NMDS Group logo

NMDS Group

pdf Publications


default Cytomorphology review of 100 newly diagnosed lower-risk MDS patients in the European LeukemiaNet MDS (EUMDS) registry reveals a high inter-observer concordance (4 downloads) New
default Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related disease (1 download)
default The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes (2 downloads)
default Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel (69 downloads)
default Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome (1 download)
default Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations (1 download)
default Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice (1 download)
default Evaluating Variant Calling Tools for Non-Matched Next-Generation Sequencing Data (2 downloads)
default Perturbed hematopoietic stem and progenitor cell hierarchy in myelodysplastic syndromes patients with monosomy 7 as the sole cytogenetic abnormality (159 downloads)
default GFI1(36N) as a therapeutic and prognostic marker for myelodysplastic syndrome (178 downloads)
default Mutations in histone modulators are associated with prolonged survival during azacitidine therapy (371 downloads)
default The European Hematology Association Roadmap for European Hematology Research: a consensus document (1 download)
default Aberrant splicing of genes involved in haemoglobin synthesis and impaired terminal erythroid maturation in SF3B1 mutated refractory anaemia with ring sideroblasts (343 downloads)
default Imprint of 5-azacytidine on the natural killer cell repertoire during systemic treatment for high-risk myelodysplastic syndrome (153 downloads)
default Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry (271 downloads)
default SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts (435 downloads)
default High-throughput mutational screening adds clinically important information in myelodysplastic syndromes and secondary or therapy-related acute myeloid leukemia (332 downloads)
default Self-perception of symptoms of anemia and fatigue before and after blood transfusions in patients with myelodysplastic syndromes (341 downloads)
default Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studie (263 downloads)
default Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study (333 downloads)
default A mutation in the H/ACA box of telomerase RNA component gene (TERC) in a young patient with myelodysplastic syndrome (409 downloads)
default A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine (364 downloads)
default Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo (400 downloads)
pdf Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial (347 downloads)
default Azacitidine induces profound genome-wide hypomethylation in primary myelodysplastic bone marrow cultures but may also reduce histone acetylation (339 downloads)
default Cardiac iron overload assessed by T2* magnetic resonance imaging and cardiac function in regularly transfused myelodysplastic syndrome patients (304 downloads)
default Clinical and biological implications of driver mutations in myelodysplastic syndromes (379 downloads)
default Identification of gene expression-based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes (320 downloads)
pdf Evaluation of Azacitidine in transfusion-dependent, Epo-refractory patients with lower-risk MDS ( pdf, 83 KB ) (423 downloads)
pdf Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities (294 downloads)
pdf Significance of JAK2 and TET2 mutations in myelodysplastic syndromes (346 downloads)
pdf Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy (297 downloads)
pdf Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study (280 downloads)
pdf Erythropoietin and G-CSF Treatment Associated with Improved Survival in Myelodysplastic Syndrome (345 downloads)
pdf Supportive care, growth factors, and new therapies in myelodysplastic syndromes (317 downloads)
pdf Negative Effect of DNA Hypermethylation on the Outcome of Intensive Chemotherapy in Older Patients with High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia following Myelodysplastic Syndrome (212 downloads)
pdf Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes (260 downloads)
pdf Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF (308 downloads)
pdf The WHO classification of MDS does make a difference (304 downloads)
pdf No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease (238 downloads)
pdf A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life (263 downloads)